External Beam Radiation Therapy (EBRT) for Lung Cancer Market Size (2024 – 2030)

The Global External Beam Radiation Therapy (EBRT) for Lung Cancer Market was valued at USD 6.9 billion in 2023 and is projected to reach a market size of  USD 9.71 billion by 2030. Over the forecast period of 2024-2030, market is projected to grow at a CAGR of 5%.

High-energy radiation is used in External Beam Radiation Therapy (EBRT) to target and kill lung cancer cells. These beams are directed from outside the body via a device known as a linear accelerator. EBRT can be palliative, meaning it aims to reduce symptoms like pain or dyspnea, or curative, meaning it seeks a full recovery. It can be used either on its own or in conjunction with other medical therapies like chemotherapy or surgery.

Key Market Insights:

The burden of lung cancer worldwide is expected to increase because of things like smoking and air pollution. With a projected 2.2 million deaths from lung cancer in 2020, lung cancer is the largest cause of cancer-related deaths globally.

There is a boom in innovation in the EBRT sector. Radiation therapy methods such as stereotactic radiosurgery (SRS) provide extremely accurate radiation with few side effects. SRS was able to produce an 86.2% 5-year local control rate for patients with early-stage lung cancer. When combined with fewer side effects, this increase in therapeutic efficacy is encouraging patient uptake and propelling market expansion.

Access to EBRT is expected to increase as developing nations' healthcare infrastructure gets stronger. From 2022 to2028, the Asia Pacific EBRT market for lung cancer is expected to expand at a noteworthy CAGR of 8.2.

EBRT is frequently combined with other therapies for lung cancer. Improvements in immunotherapy and targeted medicines are opening new possibilities for more potent combinations. In comparison to EBRT alone, patients with lung cancer who received immunotherapy in addition to EBRT had a considerably higher progression-free survival rate, according to a 2023 clinical study that was published in Nature Medicine. As these therapeutic approaches become more commonly used, the market for EBRT might be greatly boosted by the possibility for improved patient outcomes through combination therapy.

Global External Beam Radiation Therapy (EBRT) for Lung Cancer Market Drivers:

Increasing Rates of Lung Cancer: A Double-edged Sword for the EBRT Industry

The EBRT market is shadowed by the increased prevalence of lung cancer, yet this shadow fosters growth. The main cause of this increase is the persistence of smoking, which is a known risk factor for lung cancer. But there are other variables at play than personal preferences. One major factor is air pollution, especially in emerging nations with high levels of traffic and increasing industries. The prognosis for lung cancer diagnosis is alarming due to these variables combined. This sobering fact serves as EBRT's main market motivator. The need for efficient treatment alternatives like EBRT will increase in tandem with the growth in lung cancer occurrences. EBRT is an essential component in the management of this expanding public health issue as it provides a useful weapon in the battle against lung cancer. The market will advance as more people are diagnosed with lung cancer, which will result in a greater pool of candidates for EBRT.

Redefining Treatment Accuracy, Reducing Adverse Effects, and Increasing Patient Acceptability for Industry Development

Revolutionary developments in radiation treatment methods are driving a revival in the EBRT business. The days of wide, inaccurate radiation beams are long gone. These days, a paradigm change is possible because to cutting-edge technology like intensity-modulated radiation treatment (IMRT) and stereotactic radiosurgery (SRS). By using these procedures, radiation doses are delivered with extreme precision, minimising harm to nearby healthy tissues. Patients benefit from both better treatment outcomes and far fewer side effects because of this. Better tumour control and improved quality of life both during and after therapy are now possible for patients. With its increased tolerability, EBRT becomes a more appealing choice for a larger group of patients, which will eventually spur market uptake and advance the treatment's future.

Global External Beam Radiation Therapy (EBRT) for Lung Cancer Market Restraints and Challenges:

Despite its value, the worldwide market for EBRT for lung cancer is not without obstacles. Access may be hampered by the high cost of care and equipment, especially in areas with underdeveloped healthcare systems. Side effects like exhaustion and skin irritation can also discourage patients or make more supportive care necessary, which raises the expense of treatment even more. A competitive challenge arises from the development of alternative therapies, such as tailored drugs and minimally invasive surgery, which may provide better results or fewer side effects for some individuals. Furthermore, the availability of EBRT may be limited in some places because to a lack of qualified radiation oncologists and technicians. Finally, poor reimbursement practices for healthcare might put a financial strain on both patients and providers, which would impede the expansion of the market. These elements work together to generate obstacles that the market for EBRT for lung cancer must get beyond.

Global External Beam Radiation Therapy (EBRT) for Lung Cancer Market Opportunities:

Though there are still obstacles to overcome, the global EBRT for lung cancer market offers intriguing prospects. The growing number of lung cancer cases brought on by smoking and pollution will increase the demand for efficient therapies like EBRT. Improvements in patient outcomes and treatment uptake can be attributed to technological innovations like as intensity-modulated radiation therapy and stereotactic radiosurgery, which provide more accurate radiation with less side effects. Furthermore, there is a huge prospective market for EBRT access due to the expansion of developing nations with better healthcare facilities. Furthermore, as these complementary therapies progress, EBRT's function in combination therapies with immunotherapy and targeted medicines may be strengthened. By concentrating on early lung cancer identification, EBRT can be applied more successfully, thereby increasing the number of eligible patients. In the upcoming years, the worldwide market for EBRT for lung cancer might be greatly boosted by these variables together.

EXTERNAL BEAM RADIATION THERAPY (EBRT) FOR LUNG CANCER MARKET REPORT COVERAGE:

Global External Beam Radiation Therapy (EBRT) for Lung Cancer Market Segmentation: By Technology

• Conventional EBRT

• Advanced EBRT

It is anticipated that the market for EBRT for lung cancer would significantly change, with Advanced EBRT emerging as the leading and fastest-growing sector. Although traditional EBRT methods, such as 3D-CRT, have been used in the past, their ability to produce wider radiation fields may increase adverse effects. Conversely, Advanced EBRT presents a novel strategy utilising methods such as Intensity-Modulated Radiation Therapy (IMRT) and Stereotactic Radiosurgery (SRS). By delivering precisely tailored radiation doses, these approaches dramatically improve patient outcomes and treatment acceptability while minimising harm to healthy tissues. Advanced EBRT is rapidly gaining traction because to its emphasis on accuracy and fewer side effects, positioning it as the industry leader in the rapidly changing EBRT environment for the treatment of lung cancer.

Global External Beam Radiation Therapy (EBRT) for Lung Cancer Market Segmentation: By Application

• Curative Treatment

• Palliative Treatment

The increasing incidence of lung cancer cases, particularly with early identification when curative treatments are more advantageous, probably accounts for the increased market share held by curative treatment. The significance of curative EBRT may be cemented by early identification initiatives and EBRT technological developments that increase efficacy. Although it may be influenced by the total number of cases of lung cancer, palliative care may not expand as quickly as curative treatments. Reduced need for palliative care due to late-stage diagnoses might result from advancements in early diagnosis and treatment options. Although identifying the fastest-growing category is difficult, curative EBRT appears to have a good chance of doing so given its emphasis on increasing cure rates and possibility for early identification.

Global External Beam Radiation Therapy (EBRT) for Lung Cancer Market Segmentation: By End-User

• Hospitals

• Ambulatory Surgical Centers

• Cancer Treatment Centers

Because of their extensive infrastructure and resources for healthcare, hospitals now hold a significant market share in the EBRT for lung cancer industry. They have the trained medical personnel, such as radiation oncologists and technicians, to operate the sophisticated EBRT equipment, and they also store it. On the other hand, the fastest-growing markets are expected to be cancer treatment facilities and ambulatory surgery centres. Because ambulatory surgical centres have reduced operating expenses, they are more often doing EBRT operations, especially for less difficult cases.

Global External Beam Radiation Therapy (EBRT) for Lung Cancer Market Segmentation: By Region

• North America 

• Asia-Pacific 

• Europe 

• South America 

• Middle East and Africa

Even though North America dominates the market now, there will soon be a shift in geography for EBRT for lung cancer. Due to three factors, the Asia-Pacific region is predicted to grow at the fastest rate: an ageing population that is more susceptible to lung cancer; rising lung cancer rates that follow the global trend; and developing economies with improved healthcare infrastructure that spur access to EBRT. In the years to come, this combination of factors is probably going to push the Asia-Pacific area to the top of the lung cancer EBRT market.

COVID-19 Impact Analysis on the Global External Beam Radiation Therapy (EBRT) for Lung Cancer Market:

The COVID-19 epidemic has had a mixed effect on the market for EBRT for lung cancer. Healthcare system disruptions probably delayed the diagnosis of lung cancer and the start of EBRT, which might have a negative impact on patient outcomes and narrow the pool of patients who are eligible in the short term. Furthermore, EBRT capability may be restricted owing to overstretched resources because of COVID-19 situations. Anxieties among patients over the virus may have contributed to treatment avoidance or delays in hospitals. But the epidemic also brought with it unanticipated possibilities. Remote patient monitoring and EBRT consultations are now more accessible thanks to the growth of telehealth consultations. Following the pandemic, there may be a greater emphasis on early diagnosis, which might lead to the identification of more people as good candidates for EBRT at an earlier, more manageable stage. Moreover, it's possible that the pandemic unintentionally hastened the creation and use of new technology enabling quicker and more affordable EBRT treatment. In conclusion, even if the pandemic created some short-term difficulties, there may be a combination of long-term improvements and setbacks for the market for EBRT for lung cancer.

Recent Trends and Developments in the Global External Beam Radiation Therapy (EBRT) for Lung Cancer Market:

The market for EBRT for lung cancer is dynamically changing on a worldwide scale. Modern methods that reduce side effects and improve accuracy, including as image-guided treatment and stereotactic radiosurgery, are making EBRT a more appealing alternative for a larger group of patients. Additionally, the industry is embracing less intrusive methods and investigating extremely successful pairings between immunotherapy and targeted medicines. Additionally, developments in telehealth are making consultations and remote monitoring more accessible, and the expansion of developing countries is opening fascinating new markets. EBRT is positioned as a potent weapon in the ongoing fight against lung cancer because of its emphasis on innovation and better patient experiences.

Key Players:

1. Accuray Incorporated (US)

2. Elekta AB (Sweden)

3. IBA (Belgium)

4. Siemens Healthineers GmbH (Germany)

5. ViewRay Technologies, Inc. (US)